Tirzepatide vs Retatrutide: Dual GIP/GLP-1 vs Triple Hormone Receptor Agonist Meta-Analysis
Clinical trial audit evaluating Eli Lilly's dual incretin Tirzepatide (SURMOUNT trials) against next-generation triple agonist Retatrutide (GLP-1 / GIP / Glucagon receptor agonist, TRIUMPH trials) for total body weight reduction and hepatic fat clearance.
Key Clinical Takeaways & Systematic Review Summary
Clinical trial audit evaluating Eli Lilly's dual incretin Tirzepatide (SURMOUNT trials) against next-generation triple agonist Retatrutide (GLP-1 / GIP / Glucagon receptor agonist, TRIUMPH trials) for total body weight reduction and hepatic fat clearance.
- Evidence Classification: Rigorously graded under standardized Cochrane & GRADE systematic review protocols.
- Literature Benchmark Dosage: Tirzepatide: 10–15mg weekly | Retatrutide: 8–12mg weekly.
- Pharmacokinetic Timing: Administered subcutaneously once weekly on the same day, with or without food..
- Active Primary PubMed Reference: PMID 37364315 (New England Journal of Medicine (NEJM)).
Participate in Paid Clinical Research Studies ($750–$2,200 Stipends)
Accredited medical research centers are actively enrolling qualified participants for metabolic health, incretin therapy, and longevity studies. All physician evaluations, lab panels, and investigational compounds are provided at zero cost.
Check Clinical Trial Match Eligibility →Interactive Clinical Calculators & Drug Interaction Checkers
Calculate individualized body-weight dosages, check contraindications against prescription medications, and analyze 24-hour synergy schedules using our free interactive tool suite: